BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics MarketAccesswire • 05/15/24
BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting ObesityGlobeNewsWire • 05/08/24
BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024GlobeNewsWire • 04/30/24
BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics TechnologyGlobeNewsWire • 04/30/24
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol AmendmentGlobeNewsWire • 04/16/24
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc DiseaseGlobeNewsWire • 04/08/24
BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued WarrantsGlobeNewsWire • 04/03/24
BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual MeetingAccesswire • 02/14/24
BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-MarketGlobeNewsWire • 02/06/24
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc DiseaseGlobeNewsWire • 02/05/24
BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual MeetingGlobeNewsWire • 02/01/24
BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity ProgramGlobeNewsWire • 12/12/23
BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York CityGlobeNewsWire • 10/09/23
Roth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”Accesswire • 09/18/23
BioRestorative Therapies Enters into Supply Agreement with Evolutionary BiologicsGlobeNewsWire • 09/12/23
BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc DiseaseGlobeNewsWire • 09/08/23
As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A DrugsAccesswire • 08/30/23
BioRestorative Therapies Gains Additional Investor Confidence As Insider Dale Broadrick, CEO Lance Alstodt Purchase Thousands of SharesAccesswire • 08/02/23
Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform - Insights From The DiscussionAccesswire • 07/31/23
Insider Buying Alert: Lance Alstodt Acquires 4200 Shares of BioRestorative Therapies Inc (BRTX)GuruFocus • 07/26/23